GLP-1 for Type 2 Diabetes

In type 2 diabetes the body stops answering insulin properly and the pancreas cannot make enough extra to compensate, so blood glucose climbs. Around 37 million Americans have it, and it sits behind a great deal of the adult burden of heart disease, kidney failure and lost sight.

This drug class, along with the dual GIP and GLP-1 agonist tirzepatide, now sits near the top of the treatment order — particularly for anyone who also carries heart disease, heart failure or obesity. Ozempic and Mounjaro both hold approvals written specifically for blood sugar control in adults with the condition.

They lower glucose through several routes at once: prompting insulin release only when glucose is high, suppressing glucagon, slowing the stomach and reducing appetite. That produces real A1c reductions alongside substantial weight loss, and — unlike the older agents — carries no hypoglycemia risk on its own, absent insulin or a sulfonylurea alongside it.

As a first drug in people not yet treated, SUSTAIN-1 put semaglutide at 0.5 mg and 1.0 mg against placebo over 30 weeks, cutting A1c by 1.45% and 1.55% while the placebo group drifted up 0.02% [4].

Where the two have been compared directly, tirzepatide came out ahead. In SURPASS-2 its 10 mg and 15 mg doses lowered A1c by 2.24% and 2.30% against 1.86% for semaglutide 1 mg, and took off considerably more weight — 9.3 kg and 11.2 kg against 5.7 kg [2].

On diet and exercise alone, SURPASS-1 found tirzepatide at 5, 10 and 15 mg reducing A1c by 1.87%, 1.89% and 2.07% against placebo, which establishes it as potent without anything else alongside it [5].

Added to metformin, semaglutide beat canagliflozin in SUSTAIN-8 on both counts that matter here: A1c down 1.5% against 1.0%, and weight down 5.3 kg against 4.2 kg [7].

For people who have diabetes and obesity together, STEP-2 recorded 9.6% weight loss on semaglutide 2.4 mg against 3.4% on placebo across 68 weeks. That matters beyond the scale reading, because sustained weight loss improves insulin sensitivity directly [6].

The cardiovascular results carry at least as much weight as the glucose ones. SUSTAIN-6 found semaglutide cutting major adverse cardiac events — cardiovascular death, non-fatal heart attack, non-fatal stroke — by 26% against placebo in people at high cardiovascular risk, with a hazard ratio of 0.74 [1].

LEADER established the same kind of benefit for liraglutide: major events down 13%, and death from cardiovascular causes down 22%, against placebo in a similarly high-risk population [3].

Any adult with type 2 diabetes who is not hitting glycemic targets on diet, activity or metformin is a candidate. Current ADA and EASD guidance goes further and makes these the preferred addition wherever heart disease, failing heart function or declining kidneys are also in the picture.

The fit is strongest above a BMI of 27, because one drug then addresses both halves of the problem. Losing 10-15% of body weight, which the higher doses reach, tends to improve A1c by more than the glucose-lowering effect alone would predict.

It is the wrong choice for anyone whose own or family history includes medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and for anyone whose pancreatitis is active or recent. Check how the kidneys and liver are doing before starting.

Stomach upset — nausea, vomiting, diarrhea — is the usual reason a dose gets cut or the drug gets abandoned. It concentrates during escalation and typically settles across the following month or two. Starting low and climbing slowly is the whole mitigation.

Anyone already on insulin or a sulfonylurea can usually reduce those doses after adding one of these, but the combination needs watching for lows until the new balance is found.

Ozempic and Mounjaro carry the diabetes approvals. Wegovy and Zepbound hold weight-management approvals, and lower blood sugar too in anyone who has diabetes. Which formulation you end up on is a prescribing decision, and it affects coverage as much as it affects effect.

Expect A1c checks roughly quarterly at first and twice yearly once things are steady, with kidney function reviewed alongside. That is ordinary standard of care rather than extra vigilance.

Coverage for the diabetes-labeled products is generally far better than for the weight-labeled ones, and manufacturer savings programs can cut what commercially insured patients actually pay by a substantial margin.